---
title: "CRVS.US (CRVS.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CRVS.US/news.md"
symbol: "CRVS.US"
name: "CRVS.US"
parent: "https://longbridge.com/en/quote/CRVS.US.md"
datetime: "2026-05-19T11:01:54.752Z"
locales:
  - [en](https://longbridge.com/en/quote/CRVS.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CRVS.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CRVS.US/news.md)
---

# CRVS.US (CRVS.US) — Related News

### [Corvus Pharmaceuticals (CRVS) Gets a Buy from Oppenheimer](https://longbridge.com/en/news/286564149.md)
*2026-05-15T12:02:12.000Z*
> Oppenheimer's Jeff Jones has reiterated a Buy rating on Corvus Pharmaceuticals (CRVS) with a price target of $33.00. Jon

### [Top 10 US Stock Losers (5.14)](https://longbridge.com/en/news/286474507.md)
*2026-05-14T22:00:51.000Z*
> Doximity(DOCS) fell 23%, with a trading turnover 452.3 Million USD, and a year-to-date fell 59.3%. Lightwave Logic(LWLG)

### [Eczema Therapy Phase I data released, Corvus stock price plummets](https://longbridge.com/en/news/286456684.md)
*2026-05-14T19:18:55.000Z*
> Corvus Pharmaceuticals announced the Phase 1 clinical trial data of its oral ITK inhibitor soquelitinib for the treatmen

### [Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety](https://longbridge.com/en/news/286404245.md)
*2026-05-14T11:03:00.000Z*
> Corvus Pharmaceuticals presented Phase 1 data for soquelitinib, demonstrating durable drug-free remissions and a favorab

### [07:02 ETCorvention Announces FDA 510(k) Clearance for the KardiaPSI™ Balloon Catheter](https://longbridge.com/en/news/285928827.md)
*2026-05-11T11:03:58.000Z*
> Corvention has received FDA 510(k) clearance for its KardiaPSI™ Balloon Catheter, designed for balloon aortic valvulopla

### [Corvus Pharmaceuticals (NASDAQ:CRVS) Share Price Passes Above Fifty Day Moving Average  After Earnings Miss](https://longbridge.com/en/news/285795359.md)
*2026-05-09T04:11:14.000Z*
> Corvus Pharmaceuticals (NASDAQ:CRVS) stock price surpassed its 50-day moving average of $15.52, trading at $15.55 after 

### [Corvus Pharma | 10-Q: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/285657292.md)
*2026-05-08T03:20:41.000Z*
### [Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results](https://longbridge.com/en/news/285610625.md)
*2026-05-07T20:03:53.000Z*
> The clinical advancement of Soquelitinib for atopic dermatitis is progressing, with positive results from Phase 1 cohort